Effects of KW-3635, a Specific Thromboxane A2-Receptor Antagonist, on the Development of Lupus Nephritis in NZB×NZW F1 Mice

The Japanese Journal of Pharmacology

Michiyo Kawakage¹  Etsuko Nukui¹  Akira Karasawa¹  Soichiro Sato¹  Hideaki Mizumoto¹ 

[1] Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd.

关键词: Thromboxane A2-receptor antagonist;    KW-3635;    Kidney;    Nephritis;   

DOI  :  10.1254/jjp.63.433

学科分类：药理学

来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society

【 摘 要 】

References(25)Cited-By(5)ABSTRACT-We examined the effect of KW-3635, a specific thromboxane A2 (TXA2)-receptor antagonist, on the development of lupus nephritis in NZB × NZW Fl mice. KW-3635 was orally given once a day for 33 weeks beginning at eight weeks of age. In the control group, the mice began to die at 39 weeks of age, showing severe proteinuria and histopathologic abnormality in the renal glomeruli. Administration of KW-3635 (30 mg/kg/day) significantly reduced urinary protein excretion (1.7±0.9 vs. 8.5±2.4 mg/6 hr/mouse, P<0.01), mortality (1/18 vs. 6/19, P<0.05) and the histopathologic score of the kidney examined at 41 weeks of age. Thus, chronic administration of KW-3635 markedly attenuated the renal disease in NZB x NZW F1 mice, suggesting that TXA2 is an important mediator of the pathogenesis in this murine model of lupus nephritis.

【 授权许可】

Unknown